EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine

Mohammad Dweib iD, Hussein Hallak, Hani Hour, Asmahan Alzeer, Raya Fatafta, Leen Albaw

Cancer Reports · 2025

DOI: 10.1002/cnr2.70251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Mohammad Dweib und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Public Health, Al-Quds University, Jerusalem, Palestine. Hauptthemen laut MEDLINE: Dihydropyrimidine Dehydrogenase Deficiency, Dihydrouracil Dehydrogenase (NADP), Health Knowledge, Attitudes, Practice, Medical Oncology. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals.

Aim

This study aimed to assess the knowledge and opinions of HCPsspecializing in oncology in Palestine regarding screening for DPYD testing prior to prescribing FP.

Methods

A cross‐sectional survey was distributed to 106 HCPs across various hospitals in Palestine.

Results

A notable deficiency in training and implementation of pharmacogenomics was observed, with over 70% of participants lacking formal training in the field. Although there is high awareness of DPD deficiency and its impact, fewer than 50% of participants screen for DPD deficiency prior to prescribing fluoropyrimidines (FP). Standardization and promotion of DPD testing are low, and guidelines for prescribing FP are lacking, leading to variations in clinical practice.

Conclusion

These findings highlight the need for enhanced training, standardized protocols, and increased awareness to improve patient safety and outcomes in cancer treatment in Palestine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydropyrimidine Dehydrogenase DeficiencyDihydrouracil Dehydrogenase (NADP)Health Knowledge, Attitudes, PracticeMedical OncologyNeoplasmsOncologistsAdultFemaleHumansMaleMiddle AgedAttitude of Health PersonnelCross-Sectional StudiesMiddle EastPharmacistsPractice Patterns, Physicians'Surveys and Questionnaires

Stichwörter der Autor:innen

cancercapecitabinefluoropyrimidinesgenetic testingpharmacogenomics

Substanzen

Dihydrouracil Dehydrogenase (NADP)

Autor:innen und Institutionen

  • College of Public Health, Al-Quds University, Jerusalem, Palestine.
  • College of Pharmacy and Medical Sciences, Hebron University, Hebron, Palestine.
  • College of Pharmacy, Al-Quds University, Jerusalem, Palestine.
  • Palestinian Ministry of Health, Ramalla, Palestine.

ORCID-Profile: Mohammad Dweib

Zitieren

APA

Dweib, M., Hallak, H., Hour, H., Alzeer, A., Fatafta, R., & Albaw, L. (2025). Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine. Cancer Reports. https://doi.org/10.1002/cnr2.70251

Vancouver

Dweib M, Hallak H, Hour H, Alzeer A, Fatafta R, Albaw L. Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine. Cancer Reports. 2025. doi:10.1002/cnr2.70251

BibTeX
@article{Dweib2025,
  author = {Dweib, Mohammad and Hallak, Hussein and Hour, Hani and Alzeer, Asmahan and Fatafta, Raya and Albaw, Leen},
  title = {Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70251}
}
Kostenlos starten →